Related Experiment Video
Updated: Aug 4, 2026
Cefoperazone-treated Mouse Model of Clinically-relevant Clostridium difficile Strain R20291
Published on: December 10, 2016
[A clinical study of cefoxitin in children (author's transl)]
Insights
Cefoxitin, a new cephamycin antibiotic, showed a 73.3% efficacy rate in treating infantile infections like respiratory tract infections and meningitis. This study evaluated its effectiveness and side effects in young patients.
Area of Science:
- Pediatric Infectious Diseases
- Pharmacology
- Clinical Microbiology
Background:
- Cefoxitin is a novel cephamycin antibiotic.
- Infantile infections pose significant health challenges.
- Evaluating new antibiotic efficacy in pediatric populations is crucial.
Observation:
- Clinical trials involved 17 infantile patients with various infections, including respiratory tract infections, meningitis, and sepsis.
- Cefoxitin was administered intravenously at 50-104 mg/kg/day.
- Two patients were excluded from efficacy assessment due to unrelated conditions.
Findings:
- Cefoxitin demonstrated good clinical efficacy in 11 patients, fair in 2, and poor in 2, resulting in an overall efficacy rate of 73.3%.
- Observed side effects in 4 patients included eosinophilia, skin rash, and transient elevations in liver enzymes (GOT, GPT) and LDH.
- The study provides data on cefoxitin's effectiveness and tolerability in pediatric patients.
Implications:
- Cefoxitin shows promise as a treatment option for specific bacterial infections in infants.
- Further research may explore optimal dosing and broader applications in pediatric infectious diseases.
- Understanding cefoxitin's side effect profile is important for safe clinical use in children.
Abstract:
Clinical trials of cefoxitin, a new cephamycin antibiotic were carried out on 17 infantile patients with infections (respiratory tract infection 15, meningitis 1 and sepsis 1). Two patients of the above patients were excluded from the clinical evaluation except side effects because diseases were out of the object of this study. Cefoxitin was given at a dose of 50-104 mg/kg/day q.i.d. except 1 patient (b.i.d.) by a single intravenous injection for 2-27 days. The clinical efficacy obtained was good in 11 patients, fair in 2 patients and poor in 2 patients. The efficacy rate was 73.3%. Side effects were observed in 4 patients (eosinophilia 1, skin rash 2 and transient elevation of GOT, GPT and LDH 1).
Related Concept Videos
00:57Antibiotic Selection
01:22Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence